Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or myelodysplastic syndrome (MDS). Total marrow and lymphoid irradiation is a targeted form of total body irradiation that uses intensity-modulated radiation therapy to target marrow, lymph node chains, and the spleen. It is designed to reduce radiation-associated side effects and maximize the radiation the

Trial Details

NCT ID

NCT06195891

Phase

PHASE1

Sponsor

City of Hope Medical Center

Status

RECRUITING

Cancer Type

Leukemia

Interventions

Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Dual-Energy Computed Tomography
Echocardiography
Fludarabine

Locations (sample)

Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

Documented informed consent of the participant
Agreement to allow the use of archival tissue from diagnostic bone marrow biopsies
If unavailable, exceptions may be granted with study primary investigator (PI) approval
Age: 60-75 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →